Foselutoclax is under clinical development by Unity Biotechnology and currently in Phase II for Wet (Neovascular / Exudative) Macular Degeneration. According to GlobalData, Phase II drugs for Wet (Neovascular / Exudative) Macular Degeneration have a 57% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Foselutoclax’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Foselutoclax overview

UBX-1325 is under development for the treatment of ophthalmological diseases such as diabetic retinopathy, diabetic macular edema, choroidal neovascularization associated with age-related macular degeneration and neovascular  age related macular degeneration. The drug candidate is a backup to UBX1967 that acts by targeting BCL2. It is administered through intravitreal route.

Unity Biotechnology overview

Unity Biotechnology develops and commercializes therapies for the treatment of age-related diseases. The company focuses on the development of senolytic medicines to eliminate senescent cells. Unity Biotechnology’s product portfolio includes UBX0101, intended for musculoskeletal diseases; and UBX1325, for age-related diseases, including diabetic retinopathy and diabetic macular edema, glaucoma and age-related macular degeneration. It involves in developing products for idiopathic pulmonary fibrosis, systemic sclerosis, chronic obstructive pulmonary disease, cognition and kidney disease. The company works in collaboration with research institutions, academic, contract research organizations to develop its product portfolio. Unity Biotechnology is headquartered in south San Francisco, California, the US.

For a complete picture of Foselutoclax’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.